Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Dioxane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL10686155 | 0.94 | — | — | |
| Water SCHEMBL11426218 | 0.94 | TTR (0.86) | — | |
| Dioxane SCHEMBL28845935 | 0.94 | TTR (0.86) | — | |
| Dioxane SCHEMBL305440 | 0.94 | — | — | |
| Dioxane SCHEMBL15882140 | 0.94 | TTR (0.86) | — | |
| Dioxane SCHEMBL23090025 | 0.94 | TTR (0.86) | — | |
| Dioxane SCHEMBL103807 | 0.94 | — | — | |
| Water SCHEMBL9161357 | 0.94 | TTR (0.86) | — | |
| Water SCHEMBL1866439 | 0.94 | TTR (0.86) | — | |
| Dioxane SCHEMBL2832209 | 0.94 | TTR (0.86) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-115843299-A | Synthesis of oligonucleotides and related compounds | 詹森生物制药有限公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3966222-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114127082-A | Modified cyclic dinucleoside compounds as STING modulators | 阿里戈斯治疗公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20200369711-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2020227421-A1 | MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| CN-110023302-A | 2,4, 5-trisubstituted 1,2, 4-triazolones as DHODH inhibitors | 拜耳股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109096321-A | A kind of preparation method of deoxyguanosine class organic synthesis intermediate | 中国医学科学院放射医学研究所 | 2018-12-28 | — | — | CN | disclosed |
| CN-108467369-A | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | 诺华股份有限公司 | 2018-08-31 | — | — | CN | disclosed |
| US-5231174-A | 2'isodideoxy-β-D-nucleosides as stable antiviral agents | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1993-07-27 | — | — | US | disclosed |
| US-5204455-A | Monomethoxytrityl protected oligonucleotides bound to a solid support | ISIS PHARMACEUTICALS, INC. | 1993-04-20 | — | — | US | disclosed |
| US-5164491-A | Large scale synthesis of oligonucleotides and their associated analogs | GILEAD SCIENCES (US) | 1992-11-17 | — | — | US | disclosed |
| US-5084445-A | Viricide used in treatment of AIDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-01-28 | — | — | US | disclosed |
| EP-0361831-B1 | ANTIVIRAL NUCLEOSIDE COMBINATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-01-22 | — | — | EP | disclosed |
| US-5077279-A | Treating AIDS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-12-31 | — | — | US | disclosed |
| WO-1990014831-A2 | 3'-AZIDO-2',3'-DIDEOXY-5-METHYLCYTIDINE ANTI-VIRAL COMPOSITION | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1990-12-13 | — | — | WO | disclosed |
| EP-0361831-A1 | Antiviral nucleoside combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-04 | — | — | EP | disclosed |
| EP-0163405-A2 | Method of rate enhancement for triester synthesis of oligonucleotides using a catalytic alcohol, and compounds for use therein | GENENTECH, INC. (US) | 1985-12-04 | — | — | EP | disclosed |
| US-4180565-A | ANTIBACTERIAL AGENTS, ANTIBIOTICS | SCHERING CORPORATION (US) | 1979-12-25 | — | — | US | disclosed |